SG10201500015TA - Methods of producing adenovirus vectors and viral preparations generated thereby - Google Patents
Methods of producing adenovirus vectors and viral preparations generated therebyInfo
- Publication number
- SG10201500015TA SG10201500015TA SG10201500015TA SG10201500015TA SG10201500015TA SG 10201500015T A SG10201500015T A SG 10201500015TA SG 10201500015T A SG10201500015T A SG 10201500015TA SG 10201500015T A SG10201500015T A SG 10201500015TA SG 10201500015T A SG10201500015T A SG 10201500015TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- adenovirus vectors
- viral preparations
- producing adenovirus
- preparations generated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29415810P | 2010-01-12 | 2010-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201500015TA true SG10201500015TA (en) | 2015-02-27 |
Family
ID=43982270
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201500015TA SG10201500015TA (en) | 2010-01-12 | 2011-01-12 | Methods of producing adenovirus vectors and viral preparations generated thereby |
SG2012051496A SG182490A1 (en) | 2010-01-12 | 2011-01-12 | Methods of producing adenovirus vectors and viral preparations generated thereby |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012051496A SG182490A1 (en) | 2010-01-12 | 2011-01-12 | Methods of producing adenovirus vectors and viral preparations generated thereby |
Country Status (6)
Country | Link |
---|---|
US (2) | US20130052165A1 (en) |
EP (1) | EP2523681A1 (en) |
JP (1) | JP6009357B2 (en) |
IL (1) | IL220922B (en) |
SG (2) | SG10201500015TA (en) |
WO (1) | WO2011086509A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
EP1436313B1 (en) | 2001-10-19 | 2010-09-22 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
CN101516902B (en) | 2006-07-31 | 2012-08-08 | 脉管生物生长有限公司 | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
CA2786377C (en) | 2010-01-05 | 2018-02-27 | Vascular Biogenics Ltd. | Compositions and methods for treating malignant gliomas employing viral vectors encoding a fas-chimera |
KR101754437B1 (en) | 2010-01-05 | 2017-07-05 | 바스큘라 바이오제닉스 리미티드 | Methods for use of a specific anti-angiogenic adenoviral agent |
AU2013333571B2 (en) | 2012-10-17 | 2017-01-19 | Vascular Biogenics Ltd. | Treatment methods using adenovirus |
CN103012591B (en) * | 2012-12-12 | 2014-05-14 | 武汉吉爱生物技术有限公司 | Monoclonal antibody for resisting Benzonase, and preparation method and application thereof |
WO2014118643A2 (en) | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
CN105378074A (en) * | 2013-03-15 | 2016-03-02 | 费城儿童医院 | Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system |
CN107603956A (en) * | 2017-08-24 | 2018-01-19 | 乾元浩生物股份有限公司 | A kind of aviadenovirus scraps of paper carrier tidal type suspension culture method |
CN107630004B (en) * | 2017-09-01 | 2021-01-15 | 康希诺生物股份公司 | Cell strain for reducing generation of replication-competent adenovirus and construction method and application thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5747340A (en) | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
US6143548A (en) * | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
EP0968284B1 (en) * | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
NZ512504A (en) * | 1998-12-31 | 2004-01-30 | Aventis Pharma Sa | Method for separating viral particles |
US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
US20070286845A1 (en) | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
WO2003039459A2 (en) * | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
US7459154B2 (en) * | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
WO2006079176A1 (en) * | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
CN101516902B (en) * | 2006-07-31 | 2012-08-08 | 脉管生物生长有限公司 | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
-
2011
- 2011-01-12 JP JP2012548518A patent/JP6009357B2/en active Active
- 2011-01-12 EP EP11706326A patent/EP2523681A1/en not_active Withdrawn
- 2011-01-12 US US13/521,691 patent/US20130052165A1/en not_active Abandoned
- 2011-01-12 SG SG10201500015TA patent/SG10201500015TA/en unknown
- 2011-01-12 WO PCT/IB2011/050137 patent/WO2011086509A1/en active Application Filing
- 2011-01-12 SG SG2012051496A patent/SG182490A1/en unknown
-
2012
- 2012-07-12 IL IL220922A patent/IL220922B/en active IP Right Grant
-
2013
- 2013-03-14 US US13/826,396 patent/US20130295053A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2013516978A (en) | 2013-05-16 |
IL220922B (en) | 2019-03-31 |
EP2523681A1 (en) | 2012-11-21 |
US20130295053A1 (en) | 2013-11-07 |
US20130052165A1 (en) | 2013-02-28 |
SG182490A1 (en) | 2012-08-30 |
WO2011086509A1 (en) | 2011-07-21 |
JP6009357B2 (en) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL220922B (en) | Methods of producing adenovirus vectors and viral preparations generated thereby | |
HK1252010A1 (en) | Affenadenorirus (gorilla) or adenoviral vectors and methods of use | |
HRP20180607T1 (en) | Cmv glycoproteins and recombinant vectors | |
EP2396343A4 (en) | Modified virus vectors and methods of making and using the same | |
HK1199892A1 (en) | Modified mini-hepcidin peptides and methods of using thereof | |
ZA201301862B (en) | Oncolytic adenoviral vectors and methods and uses related thereof | |
EP2871239A4 (en) | Cell capable of producing adeno-associated virus vector | |
IL232161B (en) | Lyophilized liposomes and methods of preparing same | |
HK1182117A1 (en) | Anti-tenascin-c a2 antibodies and methods of use -c a2 | |
EP2741745A4 (en) | Cabazitaxel formulations and methods of preparing thereof | |
IL221858A (en) | Stabilisation of viral particles | |
EP2611832A4 (en) | Anti-cxcl13 antibodies and methods of using the same | |
HK1203161A1 (en) | Peptides and methods of using same | |
EP2525817B8 (en) | Vaccine vectors and methods of enhancing immune responses | |
EP2603223A4 (en) | Recombinant tumor vaccine and method of producing such vaccine | |
HRP20181439T1 (en) | Modified sendai virus vaccine and imaging vector | |
PT2525782T (en) | Formulations of nano-carriers and methods of preparing the same | |
EP2525651A4 (en) | Novel centromeres and methods of using the same | |
PT2611530T (en) | Spray-drying apparatus and methods of using the same | |
GB201115521D0 (en) | Colorant-polyesters and methods of producing colorant-polyesters | |
EP2553105A4 (en) | Compositions and methods for the production of recombinant virus vectors | |
EP2758530A4 (en) | Shigella-derived vector and methods of using the same | |
EP2576652A4 (en) | Methods of producing polyanthracene and uses thereof | |
GB201005520D0 (en) | Stabilisation of viral particles | |
PL392690A1 (en) | Process for the preparation of hydroquinone and pyrocatechol |